Table 2 Diseases included in non-IPF studies
Studies | Year published | Medication | Diseases Included |
|---|---|---|---|
Flaherty et al. INBUILD trial | 2019 | Nintedanib | iNSIP1, uIIP2, HP3, RA-ILD4, MCTD-ILD5, SSc-ILD6 and others |
Distler et al. NCT 02597933 | 2019 | Nintedanib | SSc-ILD6 |
Maher et al. | 2020 | Pirfenidone | Unclassifiable ILD |
Behr et al. | 2021 | Pirfenidone | iNSIP1, HP3, RA-ILD4, MCTD-ILD5, SSc-ILD6, asbestos-related fibrosis |